Herein, we propose a novel intelligent DDS for microenvironment-responsive tumour targeting and controlled release based on the MEND strategy, MMP-2-triggered degradation of gelatin and hyaluronidases (Hyal)-catalysed degradation of hyaluronic acid (HA). This evidence concerns the gene MMP2 and neoplasm.